EGFR and non-small cell lung carcinoma: In this analysis, 27 patients with EGFR ex20ins near loop who received chemotherapy on first-line and 1st-line chemotherapy were included in eight NSCLC patients with EGFR ex20ins far loop, while the mPFS of patients with far loop was 15.43 months (95% CI: 4.402–26.465) longer than in the near-loop group which was 7.2 months (95% CI: 2.611–11.789) (log rank P = 0.037) (Figure 3F).